IP Library Granted Patent US 7,759,360
Granted Patent B2
US 7,759,360 · App. 10/483,458 · Granted Jul 20, 2010

Methods and materials for the treatment of testosterone deficiency in men

Assignee: Repros Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,759,360
App. No.
10/483,458
Granted
Jul 20, 2010
Kind
B2
Abstract

The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism.

Claims (7)

1. A method for increasing serum levels of testosterone in a human male with secondary hypogonadism, the method comprising administering to said male an effective amount of a composition consisting essentially of trans-clomiphene or pharmaceutically acceptable salts thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.

2. The method of claim 1 , wherein the trans-clomiphene is in a dosage of 1-200 mg per day.

3. The method of claim 2 , wherein the trans-clomiphene is in a dosage of 60 mg per day.

4. The method of claim 1 , wherein the trans-clomiphene is administered in a dosage of 1.5 mg/kg per day.

5. The method of claim 1 , wherein the composition consists essentially of 12.5 mg of trans-clomiphene or a pharmaceutically effective salt thereof.

6. The method of claim 1 , wherein the composition is in the form of a filled capsule for oral use.

7. A method for treating secondary hypogonadism in a human male, the method comprising administering to a human male in need thereof, an effective amount of a composition consisting essentially of trans-clomiphene or pharmaceutically acceptable salts thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.

Assignments (1)
CHANGE OF NAME Recorded Nov 30, 2006
From: ZONAGEN, INC.
To: REPROS THERAPEUTICS INC.
Reel/Frame 018573/0121 →
Continuity (2)
Provisional Application 6030431300 · Jul 9, 2001
Related Publication 20040241224A1 · Dec 2, 2004